PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancerAntonino Glaviano, Alan Prem Kumar, Aaron Song Chuan Foo et al.|Molecular Cancer|2023Cited by 1.9k
Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in LymphomaPatrizia Mondello, Michael R. Green, Haopeng Yang et al.|Cancer Discovery|2020Cited by 159
Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancerRyan Blawski, Eneda Toska|Cell Reports|2024Cited by 13